Compare ESTA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | URGN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2018 | 2016 |
| Metric | ESTA | URGN |
|---|---|---|
| Price | $78.00 | $47.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $86.86 | $29.29 |
| AVG Volume (30 Days) | 441.4K | ★ 808.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,208,000.00 | $1,128,000.00 |
| Revenue This Year | $28.05 | $129.09 |
| Revenue Next Year | $26.21 | $70.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $33.35 | $15.86 |
| 52 Week High | $97.59 | $48.03 |
| Indicator | ESTA | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 67.02 |
| Support Level | $63.71 | $18.23 |
| Resistance Level | $83.31 | N/A |
| Average True Range (ATR) | 4.47 | 2.41 |
| MACD | -1.34 | 0.07 |
| Stochastic Oscillator | 2.88 | 78.59 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.